Send to

Choose Destination

See 1 citation found using an alternative search:

Hosp Pharm. 2013 Jan;48(1):48-56. doi: 10.1310/hpj4801-48.test.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate tablets.

Author information

Executive Editor, The Formulary.
Drug Information Resident, Drug Information Center, Washington State University, Spokane, Washington.
Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University, Spokane, Washington.
Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495. The authors indicate no relationships that could be perceived as a conflict of interest.


Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2013 monograph topics are onperampanel, omacetaxine mepesuccinate, ocriplasmin, sodium picosulfate/magnesium oxide/anhydrous citric acid, and lomitapide. The DUE/MUE is on perampanel.

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center